Medindia

X

Intel Partners With Oregon University to Develop Precision Medicine for Cancer Treatment

by Reshma Anand on  August 22, 2015 at 2:12 PM Corporate News   - G J E 4
Intel to partner with Oregon Health & Science University on an open platform-as-a-service (PaaS) solution, called the Collaborative Cancer Cloud.
Intel Partners With Oregon University to Develop Precision Medicine for Cancer Treatment
Intel Partners With Oregon University to Develop Precision Medicine for Cancer Treatment
Advertisement

The Collaborative Cancer Cloud is a precision medicine analytics platform that allows institutions to securely share patient genomic, imaging and clinical data for lifesaving discoveries. It will enable large amounts of data from sites all around the world for analysis, while preserving the privacy and security of the data at each site.

Advertisement
The end goal is to empower researchers and doctors to help patients receive a diagnosis based on their genome and potentially arm clinicians with the data needed for a targeted treatment plan.

"By 2020, we envision this happening in 24 hours -- All in One Day. The focus is to help cancer centers worldwide—and eventually centers for other diseases—securely share their private clinical and research data with one another to generate larger datasets to benefit research and inform the specific treatment of their individual patients," said Eric Dishman from Intel Health & Life Sciences.

"With the Collaborative Cancer Cloud, the company is combining next generation Intel technologies and bio-science advancements to enable solutions that make it easier, faster, and more affordable for developers, researchers, and clinicians to understand any disease that has a genetic component, starting with Cancer," he added.

"Precision medicine is one of the biggest of the big data problems and is on the cusp of a remarkable transformation in medicine. We view genomics as the first wave of precision medicine, and we're working with our partners to drive adoption of genomic sequencers, genomic appliances, and cloud-based genomic analytics," Dishman added.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All